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Abstract: Fragment-based lead generation has proven to be an
effective means of identifying high-quality lead compounds for
drug discovery programs. However, the fragment screening sets
often used are principally comprised of sp2-rich aromatic
compounds, which limits the structural (and hence biological)
diversity of the library. Herein, we describe strategies for the
synthesis of a series of partially saturated bicyclic hetero-
aromatic scaffolds with enhanced sp3 character. Subsequent
derivatization led to a fragment collection featuring regio- and
stereo-controlled introduction of substituents on the saturated
ring system, often with formation of new stereocenters.
Fragment-based drug discovery (FBDD) is a well-estab-
lished method for generating high-quality hits and leads.[1]
The approval of the B-Raf kinase inhibitor vemurafenib
(Zelboraf) in 2011[2] and the Bcl-2 inhibitor venetoclax
(Venclexta) in 2016,[3] coupled with the ongoing evaluation
of over 20 candidates in clinical trials,[4] validates this
approach as a complementary strategy to other hit-discovery
techniques such as high-throughput screening.[5] While the
growing prevalence of fragment-based approaches is encour-
aging, evaluation of many existing fragment libraries shows
a predominance of (hetero)aromatic, “flat” compounds, with
a deficiency of chiral, sp3-rich examples.[6, 7]
Studies by Ritchie et al.[8] and Lovering et al.[9] demon-
strate improvements in project progression by, for example,
increasing the fraction of sp3 centers within molecules or
restricting the number of aromatic rings. Furthermore,
computational analysis demonstrates that greater 3D con-
formational character is observed in compounds that have
been clinically evaluated in humans, compared to those found
in commercial libraries.[10] This indicates the importance of
sp3-richness in both the design of screening collections and the
subsequent development of hits to leads.
Examples of previous studies aiming to synthesize collec-
tions of sp3-enriched fragments have been limited. Diversity-
oriented synthesis[7,11] and natural product derivatives[12] have
been used to generate 3D fragment collections, but there
remains an unmet need to access new scaffold types. Recently
there have been calls[13] for new approaches and method-
ologies for designing fragments with multiple synthetically
accessible growth vectors in three dimensions, to allow rapid
and efficient elaboration of hits to leads after initial screening,
with some early success.[14]
With these points in mind, the study described herein was
aimed at developing efficient synthetic routes to a series of
partially saturated bicyclic heteroaromatic (PSBH) fragments
with enhanced sp3 content relative to existing fragment
libraries. Compounds featuring PSBHs have been shown to
display bioactivity against a range of targets (Figure 1),[15] and
so a series of related fragments might be expected to serve
effectively as a screening collection for FBDD applications.
Figure 1. Selected examples of bioactive compounds containing func-
tionalized partially saturated bicyclic heteroaromatics (highlighted in
red).
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The targets of this study featured a variable aromatic
heterocycle fused to a partially saturated carbocycle. The
heterocycle could bear either a polar (e.g., amino) group,
which should greatly enhance aqueous solubility, a property
necessary for fragment screening at higher concentrations,[7,14]
or alternatively a hydrophobic (e.g., chloro) group, which can
forge key interactions with protein targets.[16] The synthetic
route (Scheme 1) employed a modular and divergent
approach, using simple cross-coupling and alkylation reac-
tions to install a pair of terminal olefins that could be reliably
cyclized through ring-closing metathesis (RCM).[17] This
allowed excellent control of the carbocycle ring size and the
position and orientation of the resultant endocyclic olefin
growth vector, which could undergo subsequent functional-
ization to produce a range of fragments suitable for screening
and/or further elaboration.
We selected pyrazole and pyridine as representative
aromatic heterocycles. Whilst previous studies have shown
the synthesis of related structures,[18] they have incorporated
less control over the position of the olefin and do not feature
the amino group found in many of our compounds. Further-
more, there are only very few examples where the olefin is
used as a branch point and further functionalized beyond
simple reduction.[15a,19]
Starting from readily available 3-nitro-1H-pyrazole (4), 2-
(trimethylsilyl)ethoxymethyl (SEM) protection, selective
iodination, and subsequent Suzuki coupling with potassium
vinyltrifluoroborate gave vinyl derivative 7a (Table 1).
Deprotection followed by N-alkylation with an alkyl bromide
of varying C-chain length provided metathesis precursors 9a–
c, which upon treatment with either GrubbsQ or Hoveyda-
GrubbsQ 2nd generation catalysts yielded the desired scaffolds
10a–c. Inclusion of further heteroatoms in the formation of
medium-sized partially saturated rings was achieved through
treatment of vinyl intermediate 8a with either tosylate 11
(leading, after RCM, to O-containing fragment 10d), or 3-
Boc-1,2,3-oxathiazolidine 2,2-dioxide 12, which gave access to
the N-containing scaffold 10e after allylation and metathesis.
Use of a different Suzuki coupling partner gave methyl-
substituted product 7 f, which could be elaborated to PSBH
fragment 10 f. Alternatively, direct allylation at the C-5
position of SEM-protected intermediate 5 could be achieved
upon treatment with lithium diisopropylamide (LDA) and
allyl bromide. This led, in an analogous way, to scaffolds 10g–
h with non-conjugated olefins.
A similar approach was used to generate PSBH scaffolds
from pyridine 13 (Table 2). Attempts to mask the 2-amino
group as a nitro group proved ineffective since, despite
successful cross-coupling reactions, the 2-nitropyridines were
unstable to strong base and did not undergo the desired
alkylations at the 4-methyl position. Mono-Boc protection
was also unsuitable due to poor yields in the cross-coupling
step, possibly due to catalyst chelation. The 2-amino group
could be rendered synthetically tractable, however, either
through bis-Boc protection or through substitution with a 2-
chloro group, which itself can serve as a synthetic handle.[20]
Bis-Boc substrate 14 (prepared in one step from 13) was
functionalized at the 5-position using either Suzuki coupling
(for vinyl substituents) or Stille coupling (for allyl substitu-
ents) to produce intermediates 15a,d–f. Treatment with LDA
and trapping of the resultant anion with a variable alkyl
bromide electrophile gave a range of metathesis substrates
(16a–f), which under standard ring-closing metathesis con-
ditions yielded PSBH scaffolds 17a–f. The 2-chloro substrate
18 could be allylated in the 5-position by using an excess of
i-PrMgCl·LiCl and trapping the resultant organometallic
intermediate with allyl bromide. Allylation at the 4-methyl
position and RCM gave scaffold 17g in superior yields.
Following PSBH synthesis, a series of simple one-, two-, or
three-step functionalizations were performed on selected
pyrazole and pyridine scaffolds to demonstrate the synthetic
Scheme 1. General synthetic strategy toward PSBH scaffolds 1 and
subsequent incorporation of new functionalities (2) or rings (3).
Table 1: Synthesis of pyrazole-based PSBH scaffolds.
Step
m R X A (7) B (8)[c] C (9)[d] D (10)[g]
a 0 H 85%[a] 80% 55% 45%[h]
b 0 H – – 86% 84%
c 0 H – – 55% 89%
d 0 H – – 59%[e] 65%
e 0 H – – 29%[f ] 83%
f 0 Me 76%[a] 69% 44% 90%
g 1 H 61%[b] 82% 70% 93%
h 1 H – – 36% 59%[h]
Reaction conditions: [a] R’-BF3K (1.5 equiv), Pd(dppf)Cl2·CH2Cl2
(5 mol%), K2CO3 (3.0 equiv), THF/H2O, 70 8C. [b] 5 (1.0 equiv), LDA
(1.2 equiv), CuBr (20 mol%), allyl bromide (1.2 equiv), THF, @78 8C to
RT. [c] TFA, CH2Cl2, RT. [d] NaH (1.5 equiv), alkyl bromide (1.5 equiv),
THF or DMF, 70 8C. [e] NaH (1.5 equiv), 11 (1.5 equiv), THF, 70 8C. [f ] 12
(2.0 equiv), K2CO3 (3.0 equiv), DMF, RT, 43%; thenNaH (1.5 equiv), allyl
iodide (1.5 equiv), DMF, RT, 68%. [g] Grubbs II (10 mol%), CH2Cl2,
40 8C. [h] Hoveyda-Grubbs II (10 mol%), toluene, 110 8C or CH2Cl2, RT.
THF= tetrahydrofuran, TFA= trifluoroacetic acid, DMF=N,N-dimethyl-
formamide.
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utility of the olefin p-bond as a growth vector and to generate
a variety of new stereocenters (Scheme 2).
Catalytic hydrogenation of nitropyrazoles 10a–d,f served
to reduce both the olefin p-bond and the nitro group in
moderate to good yields, revealing the latent amino function-
ality and, in the case of 19 f, creating a new stereocenter.
Other one-step reactions include aziridination, dibromina-
tion, allylic oxidation dihydroxylation, difluorocyclopropana-
tion, hydroxybromination, epoxidation, and hydroboration
(20–28) to introduce functionalities at the 4-, 5- and 6-
positions of the fused pyrazole systems. Demonstrating that
these initial products can serve as intermediates to other
fragments, the products of hydroboration can react further to
incorporate Br, F, and N substituents (30–33), whilst epoxide
26 can be opened by nucleophiles such as fluoride and hydride
to form fluorohydrin 35 and alcohol 36. Whilst the yields of
some reactions were modest, sufficient material was obtained
for full characterization and future screening campaigns.
The pyridine-based scaffolds 17a–g can undergo a similar
range of transformations. Catalytic hydrogenation and sub-
sequent acid-mediated deprotection of bis-Boc compounds
17a–f generated novel fragments, many of which include new
stereocenters (37a–f). Aziridination, dibromination, dihy-
droxylation, hydroboration, a-bromoketone formation, and
hydroxybromination were also carried out (38–43). Further
reactions included amino-alcohol (44) and epoxide (45)
Table 2: Synthesis of pyridine-based PSBH scaffolds.
Step
R n R1 R2 A (15)[b] B (16)[e] C (17)[f ]
a Boc2N 0 H H 85% 60% 95%
b Boc2N 0 H Me – 69% 94%
c Boc2N 0 H CF3 – 77% 54%
d Boc2N 0 Me H 87% 60% 94%
e Boc2N 0 Ph H 92% 68% 83%
f Boc2N 1 H H 78%
[c] 41% 65%
g Cl 1 H H 73%[d] 79% 91%
Reaction conditions: [a] Boc2O (2.5 equiv), DMAP (0.1 equiv), THF,
70 8C. [b] R’-BF3K or R’-B(MIDA) (1.5 equiv), Pd(dppf)Cl2·CH2Cl2
(10 mol%), K2CO3 (3.0 equiv), THF/H2O, 70 8C. [c] Allyltributyltin
(1.1 equiv), Pd(PPh3)4 (10 mol%), KF (2 equiv), toluene, 110 8C.
[d] i-PrMgCl.LiCl (1.5 equiv), allyl bromide (1.2 equiv), THF, @15 8C to
RT. [e] LDA (1.2 equiv), alkyl bromide (1.5 equiv), THF, @78 8C to RT.
[f ] Grubbs II (5 mol%), CH2Cl2, 40 8C. DMAP=4-dimethylaminopyri-
dine.
Scheme 2. Functionalization of PSBH scaffolds. For reaction conditions, see the Supporting Information.
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formation, both from bromohydrin 43. 3-Chloro fragments
46–51 could also be readily accessed using similar conditions.
Calculation of a range of physicochemical properties was
carried out on all of the PSBH products. Almost all fragments
were shown to conform to the so-called “Rule of Three”, a set
of criteria commonly associated with greater hit rates in
fragment screening collections.[21] Of particular note are the
lowmean values for molecular weight (190), SlogP (1.45), and
“fraction aromatic” (0.43) and the high mean number of
chiral centres (0.88), especially when compared to existing
commercial libraries (Table 3).
In conclusion, we have developed simple, scalable routes
to a series of partially saturated pyrazole- and pyridine-based
scaffolds that can readily undergo a range of synthetic
transformations to generate a collection of sp3-rich fragments,
which are suitable for use either as screening members in
a library or as intermediates to “higher-content fragments”.
The compounds adhere to recognized guidelines for fragment
physicochemical properties, whilst displaying enhanced sp3
character and greater chirality, and providing a range of three-
dimensional growth vectors for synthetic development. It is
envisioned that the strategy could be applied to a vast range
of analogous scaffolds with varied heterocycles and substitu-
ents and that several of the functionalization reactions
detailed in Scheme 2 could be rendered asymmetric based
on related precedents.[19, 22]
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